DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE
April 12, 2002
Holiday Inn, Silver Spring, MD
NDA 20-386/S028, Cozaar™ (losartan potassium), Merck and Company, Inc.
Proposed Indication: for the treatment of type II diabetic patients with nephropathy
Special Government Employees/Consultants (voting)
Jeffrey B. Kopp, M.D.
Kidney Disease Section, Metabolic Diseases Branch
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Bldg. 10, Rm. 3N116
Bethesda, MD 20892-1268
Andrew S. Brem, M.D.
Professor in Pediatrics
Brown University School of Medicine
Director, Division of Pediatric Nephrology
Rhode Island Hospital
593 Eddy Street
Providence, RI 02902